LNSR

LENSAR, Inc.

$4.62

-15.38%
SectorHealthcareIndustryMedical DevicesCountryUnited States

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Source: Yahoo Finance
AI summary

Price & performance

1M-13.5%
3M+13.7%
YTD-48.6%
1Y-49.8%
52-week range—
Beta0.54
Full chart and returns against a benchmark

Q-Score

70/ 100

Quality against peers; 50 is the peer median.

Growth65
Risk56
Performance68
Valuation75
Profitability57
Leverage54
Sentiment45
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$51.7M+12.4%
Net income-$34.3M
Net margin-66.4%+2.0 pts
Historical fundamentals

Revenue exposure

34%of revenue from outside the US
United States66%
Europe16%
Other countries16%
Largest customer13%
Regions, segments, customers and suppliers

Valuation

LNSRIndustryP/E1.6429.61P/S1.063.49EV/EBITDA—18.38P/B3.813.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 10next report, before the open
EPS estimate$-0.14
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate